ID   RLUN016-2
AC   CVCL_E3PF
SY   RLUN016; RLUN16-2; RLUN16; F_PDO_000124
DR   CancerTools; 160945
RX   PubMed=31137590;
WW   Info; FTRP; -; https://www.fmu.ac.jp/home/trc/en/contract-research-provision/f-pdo/
CC   Group: Cancer organoid.
CC   Part of: Fukushima Translational Research Project Patient-Derived Organoids (F-PDO) collection.
CC   Population: Japanese.
CC   Doubling time: 7 days (PubMed=31137590).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 14-08-25; Version: 3
//
RX   PubMed=31137590; DOI=10.3390/cells8050481; PMCID=PMC6562414;
RA   Takahashi, Nobuhiko
RA   Hoshi, Hirotaka
RA   Higa, Arisa
RA   Hiyama, Gen
RA   Tamura, Hirosumi
RA   Ogawa, Mayu
RA   Takagi, Kosuke
RA   Goda, Kazuhito
RA   Okabe, Naoyuki
RA   Muto, Satoshi
RA   Suzuki, Hiroyuki
RA   Shimomura, Kenju
RA   Watanabe, Shinya
RA   Takagi, Motoki
RT   "An in vitro system for evaluating molecular targeted drugs using lung
RT   patient-derived tumor organoids.";
RL   Cells 8:481.1-481.18(2019).
//